NEW YORK (GenomeWeb News) – ClinXus, a non-profit biomarker alliance based in Grand Rapids, Mich., has joined the Critical Path Institute’s Predictive Safety Testing Consortium, ClinXus said today.
ClinXus was formed in 2006 using $1.5 million from the Michigan 21st Century Jobs Fund and from in-kind donations from its members, which include the Van Andel Institute, Spectrum Health, Saint Mary’s Health Care, Jasper Clinical Research & Development, Grand Valley State University, and Grand Valley Medical Specialists.
ClinXus was formed with the goal of “introducing molecular biomarkers into the clinical trial process,” and “uses the expertise and services of each member institution to provide a single point of contact for clinical research clients, as well as patients and physicians that participate in clinical studies.”
The Critical Path Institute was formed in 2005 to support the US Food and Drug Administration’s Critical Path Initiative via collaborative research programs. Its Predictive Safety Testing Consortium is a collection of pharmaceutical companies that have agreed to share and validate each other’s safety testing methods.
ClinXus said it is the first non-profit entity to join the PSTC.